The trial, which started at PGIMS Rohtak, aims to evaluate the vaccine's efficacy across 19 sites in 18 states and union territories, involving over 10,335 healthy adult participants. This significant step reflects India's commitment to combating dengue and advancing self-reliance in healthcare.
